Furthermore, the L-MOCA trial analysis identified HRD as an effective biomarker for platinum-sensitive recurrent ovarian cancer, while high PD-L1 expression in BRCAmutated patients appeared to reduce Olaparib efficacy (75). Here, CD274 is linked to ovarian cancer.